CA
NZ
UK
AU
IND
US
…
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
| Net income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
| Selling general administrative | 14.87M | 17.16M | 19.00M | 21.82M | 16.91M |
| Gross profit | -2.05M | -42.53M | -40.81M | 189.56M | 9.33M |
| Reconciled depreciation | 2.14M | 2.37M | 2.42M | 2.39M | 2.56M |
| Ebit | -61.63M | -54.02M | -61.94M | 116.61M | -63.42M |
| Ebitda | -59.49M | -51.65M | -59.52M | 120.13M | -60.76M |
| Depreciation and amortization | 2.14M | 2.37M | 2.42M | 3.52M | 2.66M |
| Operating income | -58.12M | -61.22M | -61.11M | 116.61M | -63.42M |
| Other operating expenses | 58.12M | 66.19M | 68.15M | 72.94M | 72.75M |
| Interest expense | 0.02M | 0.03M | 0.05M | 0.60M | 0.55M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 1.52M | 3.38M | 3.79M | 1.14M | 0.10M |
| Net interest income | 1.49M | 3.35M | 3.74M | 0.52M | -0.46M |
| Income tax expense | 0.00M | 0.00M | 2.25M | -1.24M | 0.00M |
| Total revenue | 0.00M | 4.97M | 7.04M | 189.56M | 9.33M |
| Total operating expenses | 50.89M | 18.68M | 20.30M | 72.94M | 72.75M |
| Cost of revenue | 2.05M | 47.50M | 47.84M | - | - |
| Total other income expense net | -3.52M | 7.18M | -0.88M | 1.24M | -0.36M |
| Net income from continuing ops | -61.65M | -54.04M | -59.63M | 117.85M | -63.78M |
| Net income applicable to common shares | - | - | - | 117.85M | -63.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Intangible assets | 0.00M | 0.05M | 0.21M | 0.27M | 0.33M |
| Other current assets | 1.91M | 4.56M | 3.83M | 3.91M | 92.38M |
| Total liab | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Total stockholder equity | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
| Other current liab | 8.88M | 8.89M | 8.46M | 8.65M | 12.50M |
| Common stock | 4.04M | 4.04M | 3.63M | 3.60M | 3.23M |
| Capital stock | 4.04M | 4.04M | 3.63M | 3.60M | 3.23M |
| Retained earnings | -311.75M | -246.29M | -191.75M | -127.78M | -250.95M |
| Other liab | - | - | - | 6.19M | 13.66M |
| Cash | 82.65M | 63.87M | 186.89M | 87.95M | 71.81M |
| Total current liabilities | 11.03M | 10.79M | 14.42M | 17.25M | 46.87M |
| Current deferred revenue | - | - | 4.33M | 6.41M | 28.31M |
| Net debt | -79.01M | -61.43M | -183.24M | -83.10M | -65.77M |
| Short term debt | 1.21M | 1.22M | 1.21M | 1.20M | 1.19M |
| Short long term debt total | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Other stockholder equity | 388.05M | 383.89M | 364.55M | 360.32M | 355.01M |
| Property plant equipment | - | - | - | 7.24M | 8.15M |
| Total current assets | 96.88M | 154.28M | 192.46M | 254.75M | 164.19M |
| Net tangible assets | - | - | - | 234.90M | 106.96M |
| Short term investments | 10.40M | 85.56M | 119.58M | 161.20M | 61.00M |
| Net receivables | 1.91M | 0.29M | 1.75M | 1.70M | 25.73M |
| Inventory | - | - | - | - | -86.73M |
| Accounts payable | 0.94M | 0.68M | 0.41M | 1.00M | 4.86M |
| Accumulated other comprehensive income | - | - | 0.00M | -0.98M | - |
| Non currrent assets other | - | - | 0.21M | - | 0.00M |
| Non current assets total | 5.23M | 4.25M | 5.89M | 7.51M | 8.48M |
| Capital lease obligations | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 71.54M | 40.49M | 61.08M | -101.12M | -21.00M |
| Change to liabilities | - | - | - | -30.53M | -8.99M |
| Total cashflows from investing activities | 72.55M | 40.49M | 44.64M | -101.12M | -22.24M |
| Net borrowings | -1.21M | -1.21M | -1.20M | -1.19M | -1.18M |
| Total cash from financing activities | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
| Change to operating activities | - | - | - | -0.74M | -2.30M |
| Net income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
| Change in cash | 18.78M | -3.44M | -20.64M | 16.13M | -61.91M |
| Begin period cash flow | 63.87M | 67.31M | 87.95M | 71.81M | 133.72M |
| End period cash flow | 82.65M | 63.87M | 67.31M | 87.95M | 71.81M |
| Total cash from operating activities | -51.26M | -59.25M | -59.01M | 118.57M | -90.95M |
| Issuance of capital stock | 0.00M | 17.34M | 0.00M | 0.00M | 51.49M |
| Depreciation | 2.14M | 2.37M | 2.42M | 2.39M | 2.56M |
| Other cashflows from investing activities | 1.73M | 4.22M | 3.83M | 0.49M | 0.07M |
| Change to account receivables | 0.46M | -0.35M | -0.93M | 25.26M | -23.37M |
| Sale purchase of stock | - | 0.00M | -0.00M | -0.63M | - |
| Other cashflows from financing activities | -1.46M | -1.70M | 0.03M | 0.25M | 0.27M |
| Change to netincome | - | - | - | 4.33M | 4.93M |
| Capital expenditures | 0.71M | 0.72M | 0.57M | 1.42M | 1.31M |
| Change in working capital | 1.16M | -3.80M | -6.01M | -6.01M | -34.67M |
| Stock based compensation | 4.42M | 4.11M | 5.21M | 5.09M | 4.08M |
| Other non cash items | 2.67M | -7.88M | 1.36M | -0.75M | 0.85M |
| Free cash flow | -51.97M | -59.97M | -59.81M | 117.15M | -92.26M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MOLN Molecular Partners AG ADR |
0.05 1.42% |
3.58 | - | 1.70 | 156.56 | 2.16 | 3.81 | 1.23 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 1975 |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Exec. VP of Projects & Member of Management Board | 1972 |
| Mr. Andreas Emmenegger E.M.B.A. | Advisor | 1966 |
| Mr. Alexander Zurcher | COO & Member of Management Board | NA |
| Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA | Chief Medical Officer & Member of Management Board | 1973 |
| Ms. Renate Gloggner | Exec. VP of People & Community and Member of Management Board | NA |
| Mr. Daniel Steiner Ph.D. | Sr. VP of Research | NA |
| Mr. Seth D. Lewis | Sr. VP of Investor Relations, Communications & Strategy | NA |
| Mr. Michael Pitzner | Gen. Counsel, Compliance Officer & Sr. VP of Legal | NA |
| Mr. Thomas Schwerzmann | VP of HR | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...